US Pharma MarketingThe post Bial concludes treatment period in Phase IIb ACTIVATE trial for PD appeared first on Clinical Trials Arena.
Bial concludes treatment period in Phase IIb ACTIVATE trial for PD
Bial has completed the treatment in its Phase IIb ACTIVATE clinical trial evaluating BIA 28-6156 in PD patients with a pathogenic mutation in GBA-PD. Top line results from the Phase IIb GBA-PD clinical trial are anticipated by the end of the second quarter. The ACTIVATE study assesses safety, efficacy, pharmacodynamics, pharmacokinetics, and tolerability of BIA 28-6156 in GBA-PD patients. Credit: Chinnapong / Shutterstock.com. Bial has completed the treatment in its Phase IIb ACTIVATE clinical trial evaluating BIA 28-6156 (pariceract) in Parkinson’s disease (PD) pents with a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene, GBA-PD. The 78-week, double-blind treatment period…
Bial has completed the treatment in its Phase IIb ACTIVATE clinical trial evaluating BIA 28-6156 in PD patients with a pathogenic mutation in GBA-PD.
Source: Clinical Trials Arena